recombinant 9-valent Human Papillomavirus Vaccine (9vHPV)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for recombinant 9-valent Human Papillomavirus Vaccine (9vHPV), covering 2024-02-07 to 2024-02-07. Get the full timeline:
Most recent: Clinical Trial Update: Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years [Phase 3]